TY - JOUR
T1 - Single-cell RNA-seq reveals developmental plasticity with coexisting oncogenic states and immune evasion programs in ETP-ALL
AU - Anand, Praveen
AU - Guillaumet-Adkins, Amy
AU - Dimitrova, Valeriya
AU - Yun, Huiyoung
AU - Drier, Yotam
AU - Sotudeh, Noori
AU - Rogers, Anna
AU - Ouseph, Madhu M.
AU - Nair, Monica
AU - Potdar, Sayalee
AU - Isenhart, Randi
AU - Kloeber, Jake A.
AU - Vijaykumar, Tushara
AU - Niu, Leili
AU - Vincent, Tiffaney
AU - Guo, Guangwu
AU - Frede, Julia
AU - Harris, Marian H.
AU - Place, Andrew E.
AU - Silverman, Lewis B.
AU - Teachey, David T.
AU - Lane, Andrew A.
AU - DeAngelo, Daniel J.
AU - Aster, Jon C.
AU - Bernstein, Bradley E.
AU - Lohr, Jens G.
AU - Knoechel, Birgit
N1 - Publisher Copyright:
© 2021 American Society of Hematology
PY - 2021/5/6
Y1 - 2021/5/6
N2 - Lineage plasticity and stemness have been invoked as causes of therapy resistance in cancer, because these flexible states allow cancer cells to dedifferentiate and alter their dependencies. We investigated such resistance mechanisms in relapsed/refractory early T-cell progenitor acute lymphoblastic leukemia (ETP-ALL) carrying activating NOTCH1 mutations via full-length single-cell RNA sequencing (scRNA-seq) of malignant and microenvironmental cells. We identified 2 highly distinct stem-like states that critically differed with regard to cell cycle and oncogenic signaling. Fast-cycling stem-like leukemia cells demonstrated Notch activation and were effectively eliminated in patients by Notch inhibition, whereas slow-cycling stem-like cells were Notch independent and rather relied on PI3K signaling, likely explaining the poor efficacy of Notch inhibition in this disease. Remarkably, we found that both stem-like states could differentiate into a more mature leukemia state with prominent immunomodulatory functions, including high expression of the LGALS9 checkpoint molecule. These cells promoted an immunosuppressive leukemia ecosystem with clonal accumulation of dysfunctional CD8+ T cells that expressed HAVCR2, the cognate receptor for LGALS9. Our study identified complex interactions between signaling programs, cellular plasticity, and immune programs that characterize ETP-ALL, illustrating the multidimensionality of tumor heterogeneity. In this scenario, combination therapies targeting diverse oncogenic states and the immune ecosystem seem most promising to successfully eliminate tumor cells that escape treatment through coexisting transcriptional programs.
AB - Lineage plasticity and stemness have been invoked as causes of therapy resistance in cancer, because these flexible states allow cancer cells to dedifferentiate and alter their dependencies. We investigated such resistance mechanisms in relapsed/refractory early T-cell progenitor acute lymphoblastic leukemia (ETP-ALL) carrying activating NOTCH1 mutations via full-length single-cell RNA sequencing (scRNA-seq) of malignant and microenvironmental cells. We identified 2 highly distinct stem-like states that critically differed with regard to cell cycle and oncogenic signaling. Fast-cycling stem-like leukemia cells demonstrated Notch activation and were effectively eliminated in patients by Notch inhibition, whereas slow-cycling stem-like cells were Notch independent and rather relied on PI3K signaling, likely explaining the poor efficacy of Notch inhibition in this disease. Remarkably, we found that both stem-like states could differentiate into a more mature leukemia state with prominent immunomodulatory functions, including high expression of the LGALS9 checkpoint molecule. These cells promoted an immunosuppressive leukemia ecosystem with clonal accumulation of dysfunctional CD8+ T cells that expressed HAVCR2, the cognate receptor for LGALS9. Our study identified complex interactions between signaling programs, cellular plasticity, and immune programs that characterize ETP-ALL, illustrating the multidimensionality of tumor heterogeneity. In this scenario, combination therapies targeting diverse oncogenic states and the immune ecosystem seem most promising to successfully eliminate tumor cells that escape treatment through coexisting transcriptional programs.
UR - http://www.scopus.com/inward/record.url?scp=85103037707&partnerID=8YFLogxK
U2 - 10.1182/blood.2019004547
DO - 10.1182/blood.2019004547
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???
C2 - 33227818
AN - SCOPUS:85103037707
SN - 0006-4971
VL - 137
SP - 2463
EP - 2480
JO - Blood
JF - Blood
IS - 18
ER -